Prognostic value of inflammation‐related biomarkers in patients with gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta‐analysis
- 11 March 2024
- journal article
- research article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 36 (4) , e13381
Abstract
Hematological indicators of chronic systemic inflammation are significant biomarkers for gastroenteropancreatic neuroendocrine neoplasms (GEP‐NENs). We performed a systematic review and meta‐analysis to assess the impact of certain factors on the overall survival (OS), progression‐free survival (PFS), and disease‐free survival (DFS) of patients with GEP‐NENs. These factors include the neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), and C‐reactive protein (CRP) levels. After searching the Medline, Embase, and Cochrane Library databases from January 1, 2000 to October 20, 2022 and the American Society of Clinical Oncology conference proceedings from January 1, 2017, hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted. Subgroup analyses were conducted to identify the origins of heterogeneity and examine the impact of factor grouping. The effects of the cut‐off values and sample size were assessed by meta‐regression. The results revealed that higher NLRs, PLRs, and CRP levels were associated with shorter OS (HR = 2.09, 95% CI = 1.55–2.8; HR = 1.79, 95% CI = 1.40–2.28; and HR = 2.88, 95% CI = 2.09–3.95, respectively; all p < 0.001). Higher NLRs and lower LMRs were associated with shorter DFS (HR = 3.34, 95% CI = 2.11–5.29 and HR = 2.71, 95% CI = 2.27–3.24, respectively; both p < 0.001). Higher PLRs and CRP levels were correlated with shorter PFS (HR = 3.48, 95% CI = 1.34–9.03, p = 0.01 and HR = 3.14, 95% CI = 1.63–6.08, p = 0.001). As demonstrated in the research, hematological indicators of systemic inflammation are promising biomarkers for GEP‐NEN assessment.Keywords
This publication has 40 references indexed in Scilit:
- Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: A meta-analysis of results from multivariate analysisInternational Journal of Surgery, 2022
- Papel de los factores inflamatorios sistémicos en los tumores neuroendocrinos gastroenteropancreáticos (TNE-GEP) tratados con péptidos marcados con radionúclidos (PRRT): de la biología a la teragnosisRevista Española de Medicina Nuclear e Imagen Molecular, 2022
- Inflammation: the incubator of the tumor microenvironmentTrends in Cancer, 2022
- Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 ( 177 Lu)-DOTATATE in Patients with Advanced Neuroendocrine TumorsCancer Biotherapy and Radiopharmaceuticals, 2022
- Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumorsAnti-Cancer Drugs, 2020
- Prognostic significance of neutrophil–lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophagesPancreatology, 2019
- Association of preoperative monocyte‐to‐lymphocyte and neutrophil‐to‐lymphocyte ratio with recurrence‐free and overall survival after resection of pancreatic neuroendocrine tumors (US‐NETSG)Journal of Surgical Oncology, 2019
- Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancerLung Cancer, 2018
- Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patientsMelanoma Research, 2017
- Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United StatesJAMA Oncology, 2017